Exosome Diagnostics, Inc., a subsidiary of MDxHealth SA, released its financial results for the year ended June 30, 2025. For the reported period, Exosome Diagnostics, Inc. recognized revenues from services performed for customers, including laboratory testing and custom development projects. Laboratory testing is performed on samples collected by medical professionals and research laboratories using the company’s biofluid-based molecular diagnostic test. Revenue also included royalty revenues, recognized in the period the related sales occurred. During the year, all 1,000 shares of common stock, with a par value of $0.001 per share, remained owned by the company’s parent. No other significant subsequent events, except for the sale of the company, were identified. A key operational update was the sale of Exosome Diagnostics, Inc. On September 15, 2025, the company was sold to MDxHealth SA for approximately $15 million. No significant variations in revenues or net income compared to the previous period were disclosed in the reported results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MDxHealth SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-014925), on February 11, 2026, and is solely responsible for the information contained therein.